Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

332 results about "Risk groups" patented technology

High-risk group. Epidemiology A group of people in the community with a higher-than-expected risk for developing a particular disease, which may be defined on a measurable parameter–eg, an inherited genetic defect, physical attribute, lifestyle, habit, socioeconomic and/or educational feature, as well as environment.

Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC

Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers

InactiveUS20070105165A1Increased relapse riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4

Intelligent voice-controlled voiceprint and face authentication access control system and method

The invention discloses an intelligent voice-controlled voiceprint and face authentication access control system and a method. The system includes a gate host, an indoor host and a central server. Through voice control, the system avoids picking up the key, pressing button, checking fingerprint or other complex operation, especially the awkwardness for opening the door when items are held in the hands; the voiceprint and face recognition are combined to achieve a high security level, which is more secure than the traditional key, password lock and fingerprint lock. The access control system provided by the invention has basically the same shape and use method as the traditional visual intercom access control system and the visual doorbell, and is easy to be accepted by users; compared with the traditional visual intercom access control system and the visual doorbell, the access control system provided by the invention has additional no disturb function, which can be set aiming at the unwanted visitors like salesman. The access control system provided by the invention has community joint defense and linkage function, the control center can timely transfer high risk warning information, and control the host to automatically and timely warn high-risk groups (wanted suspects, etc.), so as to effectively avoid the occurrence of malignant cases, and protect the safety of the user's life and property.
Owner:赵树龙

A relevant failure prediction method and system

The invention provides a relevant failure prediction method and system. The relevant failure prediction method comprises the steps of acquiring historical failure information of a distributive computing system and acquiring a failure information sample database according to the historical failure information; acquiring effective failure information in the failure information sample database and performing time discretization processing on the effective failure information to obtain a sample data matrix; acquiring a current probability shared risk group structure of the distributive computing system according to the sample data matrix; acquiring current failure sample information of the distributive computing system that is collected in real time; performing failure prediction on the distributive computing system according to the current probability shared risk group structure and the current failure sample information. The method and the system can describe the diversity and transmissibility characteristics of relevant failures comprehensively and accurately, improve prediction precision, effectively increase the prediction method execution efficiency and facilitate online failure deployment and implementation, and are of great importance for improving the availability and the reliability of the distributive computing system.
Owner:ZHUHAI POWER SUPPLY BUREAU GUANGDONG POWER GIRD CO

Therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2

The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
Owner:MOGAM BIOTECH RES INST

Method and system for performing orthotopic liver transplantation prognosis condition grouping on hepatocellular carcinoma patient with single tumor

The invention relates to a method for performing prognosis condition grouping on a hepatocellular carcinoma patient who has single tumor and is about to be subjected to or is already subjected to orthotopic liver transplantation. The method comprises the steps of (1) obtaining a sample from general samples after transhepatic biopsy before transplantation or liver transplantation, and detecting CK19 and GPC3 expression conditions of tumor cells in the hepatocellular carcinoma tissue sample of the patient; (2) detecting and recording a maximum diameter of the tumor of the patient; (3) detecting and recording a serum alpha-fetoprotein level of the patient; and (4) based on a pathological section, observing whether microvascular invasion exists or not. Recurrent risks are scored according to beta coefficients of four factors in COX regression analysis; scores in items are subjected to addition; a recurrent risk group with a total score less than or equal to 4 is determined as a low recurrent risk group; a recurrent risk group with a total score equal to 5-7 is determined as a medium recurrent risk group; and a current risk group with a total score more than or equal to 8 is determined as a high recurrent risk group. Through the method, an effective auxiliary information value can be provided for a doctor and the patient; and tumor recurrence or transfer is closely monitored, so that health conditions can be discovered within the shortest time, the doctor and the patient are effectively prompted, and people are reminded to timely examine body conditions.
Owner:冯德昭 +1

Sense-antisense gene pairs for patient stratification, prognosis, and therapeutic biomarkers identification

InactiveUS20160259883A1Quality improvementHighly prognostically significantMicrobiological testing/measurementLibrary screeningPrognostic signaturePatient stratification
The present invention relates to a method of identification of clinically and genetically distinct sub-groups of patients subject to a medical condition, particularly breast, lung, and colon cancer patients using a composition of respective gene expression values for certain gene pairs. Sense-antisense gene pairs (SAGPs) which are relevant for a medical condition and the disease prognosis are used by the method to generate statistical models based on the expression values of the SAGPs. SAGPs for which the statistical models are found to have high value in prognosis of the variation of medical condition and the diseases are selected and integrated in the prognostic signature including specified parameters (e.g. cut-off values) of the prognostic model. It further relates to using respective gene expression values for these genes to predict patient′ risk groups (in context of patient's survival or / and disease progression) and to using the predicted groups for identification of patient risk, and specific and robust prognostic biomarkers with mechanistic interpretations of biological changes (associated with the gene signatures) appropriating for an implementation of therapeutic targeting.
Owner:AGENCY FOR SCI TECH & RES

Molecular markers, internal reference genes and application thereof, detection kit and method for constructing detection model

ActiveCN107574243AImproving technical methods in prognostic predictionMeet the needs of individualized precision treatmentMicrobiological testing/measurementDNA/RNA fragmentationReference genesLow risk group
The invention especially relates to molecular markers, internal reference genes and application thereof, a detection kit and a method for constructing a detection model, belonging to the field of biotechnology. With follow-up information used for comparison, the kit provided by the invention has accuracy of 70% in predication of the risk of recurrence or death of first-visit patients with ER-positive and PR-positive breast cancers in 3-10 years after operations, wherein the prediction accuracies of a low-risk group and a high-risk group are 81.1% and 54.4%, respectively while the prediction accuracies of corresponding FFPE pathological examination results are 71.9 to 56.8%, respectively. The risk prediction model matching with the kit only needs the Ct values of the molecular markers, theage of a patient, the stage of pT and the number of LN and does not depend on other clinical pathological information, so the risk prediction model has better performance in evaluation of prognosis ofbreast cancers than simple pathological prediction results, can reduce malpractice caused by errors in pathological prediction and further improves a technical method for evaluation of prognosis of breast cancers.
Owner:CAPITALBIO CORP +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products